Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma

[1]  A. Giordano,et al.  PRMT5 silencing selectively affects MTAP‐deleted mesothelioma: In vitro evidence of a novel promising approach , 2020, Journal of cellular and molecular medicine.

[2]  S. Sleijfer,et al.  The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs , 2019, Nature.

[3]  Z. Feng,et al.  Downregulating STAT1/caspase‐3 signaling with fludarabine to alleviate progression in a rat model of steroid‐induced avascular necrosis of the femoral head , 2018, Journal of biochemical and molecular toxicology.

[4]  P. V. Van Schil,et al.  Multimodality treatment of malignant pleural mesothelioma , 2018, F1000Research.

[5]  A. Giordano,et al.  Possible repurposing of pyrvinium pamoate for the treatment of mesothelioma: A pre‐clinical assessment , 2018, Journal of cellular physiology.

[6]  N. Maskell,et al.  Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial , 2018, Trials.

[7]  A. Karpeisky,et al.  Bisphosphonate conjugation for bone specific drug targeting , 2018, Bone reports.

[8]  N. André,et al.  Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? , 2018, European Respiratory Review.

[9]  W. Rokicki,et al.  Malignant mesothelioma as a difficult interdisciplinary problem , 2017, Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery.

[10]  M. Stockler,et al.  Bisphosphonates and other bone agents for breast cancer. , 2017, The Cochrane database of systematic reviews.

[11]  K. Selander,et al.  A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma , 2017, Lung Cancer.

[12]  W. Ni,et al.  Fludarabine inhibits STAT1-mediated up-regulation of caspase-3 expression in dexamethasone-induced osteoblasts apoptosis and slows the progression of steroid-induced avascular necrosis of the femoral head in rats , 2017, Apoptosis.

[13]  T. Robak,et al.  Older and new purine nucleoside analogs for patients with acute leukemias. , 2013, Cancer treatment reviews.

[14]  H. Bluyssen,et al.  In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. , 2013, European journal of pharmacology.

[15]  M. Kalaycio,et al.  Fludarabine: a review of the clear benefits and potential harms. , 2013, Leukemia research.

[16]  M. Gnant,et al.  Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. , 2012, Cancer treatment reviews.

[17]  J. Bujnicki,et al.  STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. , 2011, Cytokine & growth factor reviews.

[18]  R. Stahel,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. Curcio,et al.  Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. , 2007, American journal of physiology. Heart and circulatory physiology.

[20]  T. Wilt,et al.  Bisphosphonates for advanced prostate cancer. , 2006, The Cochrane database of systematic reviews.

[21]  F. Ricci,et al.  Role of fludarabine in hematological malignancies , 2006, Expert review of anticancer therapy.

[22]  J. Briones,et al.  Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia , 2005, Leukemia & lymphoma.

[23]  A. Lipton.  Toward new horizons: the future of bisphosphonate therapy. , 2004, The oncologist.

[24]  J. Gribben,et al.  Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. , 2004, Leukemia research.

[25]  P. Clézardin.  The antitumor potential of bisphosphonates. , 2002, Seminars in oncology.

[26]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[27]  J. Mackey,et al.  Nucleoside analogues: mechanisms of drug resistance and reversal strategies , 2001, Leukemia.

[28]  N. Sacco-Gibson,et al.  Dose‐Proportional Pharmacokinetics of Risedronate on Single‐Dose Oral Administration to Healthy Volunteers , 2000, Journal of clinical pharmacology.

[29]  G. Keszler,et al.  Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. , 1999, European journal of cancer.

[30]  G. Peters,et al.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 , 1999, British journal of haematology.

[31]  J. Ritz,et al.  Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling , 1999, Nature Medicine.

[32]  D. Kufe,et al.  Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. , 1986, Biochemical pharmacology.

[33]  P. Zucali.  Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma. , 2018, Journal of thoracic disease.

[34]  Mathias Müller,et al.  The good and the bad faces of STAT1 in solid tumours. , 2017, Cytokine.

[35]  A. Heidenreich,et al.  Bisphosphonates for advanced prostate cancer. , 2017, The Cochrane database of systematic reviews.

[36]  P. V. Van Schil,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  I. Ahmed,et al.  Malignant mesothelioma , 2013, Pakistan journal of medical sciences.

[38]  D. Figgitt,et al.  Oral Fludarabine , 2012, Drugs.

[39]  M. Jahanzeb,et al.  The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer. , 2011, Clinical lung cancer.

[40]  H. Bluyssen,et al.  STAT activation and differential complex formation dictate selectivity of interferon responses. , 2007, Acta biochimica Polonica.

[41]  P. Hillmen.  Future prospects for fludarabine-containing regimens in the treatment of hematological cancers. , 2004, The hematology journal : the official journal of the European Haematology Association.

[42]  J. Cyong,et al.  Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies , 2003, Journal of Bone and Mineral Metabolism.

[43]  W. Plunkett,et al.  Cellular and Clinical Pharmacology of Fludarabine , 2002, Clinical pharmacokinetics.

[44]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.